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used data from the EuroSC study, a longitudinal cohort of 1208 patients with schizo-
phrenia followed for 2 years. Every 6 months, the collected information included 
QoL-Interview, from which the Global Satisfaction Score (GLS) and the frequency 
of social contacts score were derived, and the Positive And Negative Symptoms 
Scale (PANSS), from which EW score was derived. After bivariate and correlation 
analyses, we tested whether few social contacts at baseline would predict greater 
EW and lower GLS after 2 years when adjusted on baseline level. Finally, random-
effects regression analyses were performed to test the longitudinal effect of social 
contact, adjusting on potential confounding factors. Results: Bivariate and cor-
relation analyses established a link between frequency of social contact and both 
EW score (-0.24, p< 0.001) and negative factor scale (-0.30, p< 0.0001) at each time 
point. Few social contacts at baseline were associated with greater EW (p= 0.013) 
and worse negative factor score (p= 0.009), when compared to baseline. A trend for 
prediction of better QoL was also found, although not reaching significance. Random 
effects regressions confirmed the significant impact of social contacts over time on 
EW (p< 0.0001), negative factor score (p< 0.0001) and QoL (p< 0.001). ConClusions: 
Given consistent effects of social contacts on reduction of negative symptoms and 
improvement of QoL in schizophrenic patients, social contacts should be used as a 
therapeutic tool. A higher frequency of social contacts could be obtained by regular 
therapeutic groups offered to these patients.
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objeCtives: To examine prescription patterns of drugs for the treatment of attention 
deficit disorders in Japanese children and adolescents. Methods: We conducted a 
cross-sectional survey during October 2013 on outpatients aged 19 years or less in 34 
private mental clinics. Patients who were prescribed at least one drug for the treat-
ment of attention deficit disorders were analyzed in this report. Data were extracted 
on gender, age, principal psychiatric diagnosis (based on ICD-10), and types and 
doses of psychotropic drugs. Results: The samples consisted of 286 males and 51 
females. The average age (standard deviation) was 11.6 years (3.1). The mean length 
of psychiatric treatment was 21.3 months (24.0). The most frequent principal diag-
nostic category was “behavioral and emotional disorders with onset usually occurring 
in childhood and adolescence” (F9; n= 237), followed by “disorders of psychological 
development” (F8; n= 99), and “mental retardation” (F7; n= 1). Of 337 samples, 247 
(73.2%) were prescribedOROS methylphenidate (OROS-MPH), a psycho-stimulant, 
while 141 (41.8%) received atomoxetine (ATMX), a selective noradrenalin reuptake 
inhibitor. OROS-MPH/ATMX combination therapy was administered to 51 (15.1%) of 
337 patients. Antipsychotics were concurrently prescribed in 80 (23.7%) patients. Mood 
stabilizers were co-prescribed in 20 (5.9%) cases. Antidepressants were co-prescribed 
in 19 (5.6%) patients. Anxiolytics/hypnotics were concurrently prescribed in 13 (3.9%) 
patients. ConClusions: In Japan, nearly one-sixth of the outpatients with attention 
deficit disorders received OROS-MPH/ATMX combination therapy.
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objeCtives: Prescribing for adult psychiatric patients is often highly complex 
due to the nature of psychiatric conditions, but also due to somatic comorbid-
ity. Therefore, the aim of this study was to identify prevalence and types of 
potential inappropriate prescribing (PIP), asses the severity of potential clinical 
consequences and identify possible predictive factors of PIP. Methods: The study 
was designed as a prospective study of PIP using medication reviews. 
Patients who were admitted during a 4 month period (August 2013 - November 
2013) to a psychiatric university hospital were included (n= 219). The medi-
cation reviews, including an assessment of potential severity, were carried 
out by clinical pharmacologists after admission and after the attending physi-
cian had seen the patient. Frequencies and categories of PIP were analyzed in 
absolute numbers and as percentages. Severity of PIP was assessed using four 
categories. Logistic regression analysis was used to identify possible predic-
tive factors of PIP. Results: The proportion of patients with one or more PIPs 
was 123/219 (56%). “Interaction between drugs” was the most common category 
for potentially serious and potentially fatal PIPs with 49/123 (40%) and 32/45 (71%), 
respectively. Of 32 identified potentially fatal drug-drug interactions, 15/32 (47%) 
involved two or more antipsychotic drugs and 12/32 (37%) involved antipsychotic 
drugs in combination with antidepressants. The remaining 5/32 (16%) potentially 
fatal drug-drug interactions involved propranolol, erythromycin, simvastatin 
and promethazine. After adjusting for age, gender, alcohol/substance abuse, 
number of prescriptions, number of somatic diagnoses and level of kidney 
function, only polypharmacy (> 5 prescriptions) increased the odds for a PIP 
significantly; OR= 4,82 (95%CI: 2.33-9.98), p< 0.0001. ConClusions: PIP is 
frequent and might have serious or fatal consequences. Special attention should be 
given to drug-drug interactions involving antipsychotics and antidepressants but 
also somatic medications and polypharmacy threatens medication safety. There 
is a pressing need to improve the quality in prescribing for psychiatric patients.
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from a common Normal distribution of treatment effects with an overall SSRI class 
effect mean, and between treatment within class heterogeneity. Results: There 
were 55 eligible studies identified in the systematic review. The intervention with 
the greatest decrease in YBOCS was behavioural therapy (“exposure and response 
prevention”) showing a decrease of 13.86 (CrI 9.34 to 18.31). The second and third 
greatest decrease was cognitive therapy (12.80 CrI 7.39 to 18.18) and behavioural 
therapy plus clomipramine (12.47 CrI 5.80 to 19.08) respectively. The SSRI class effect 
showed a relative decrease in mean YBOCS of 2.89 (CrI 1.05 to 4.71) compared to 
pharmacological placebo. The results of the individual SSRIs ranged from a decrease 
of 2.49 (sertraline) to 3.10 (fluvoxamine). ConClusions: This analysis showed a 
combination of behavioural therapy plus clomipramine has the greatest decrease 
in YBOCS. There is little evidence to show a difference between SSRIs.
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objeCtives: To estimate the clinical effectiveness of augmentation of SSRI antide-
pressant therapy with either lithium or an AAP in TRD, defined as failure to respond 
to two or more antidepressants in the current episode of depression. Methods: 
Systematic review of CENTRAL, EMBASE, MEDLINE, and PsycINFO was completed 
in August 2011. Additional data were obtained from manufacturers. Studies were 
assessed for quality using the Cochrane Risk of Bias Tool. Pairwise meta-analysis 
and mixed treatment comparison (MTC) were undertaken based on intention-to-
treat analyses. Results: Of the 3,721 papers found in the literature search, 12 
randomised controlled trials (RCTs) were identified; 10 (SSRI + AAP vs SSRI + pla-
cebo/no treatment); 1 (SSRI + AAP vs SSRI + lithium); 1 (SSRI + lithium vs SSRI + 
placebo). The RCTs included in the primary analyses used fluoxetine as the SSRI and 
olanzapine as the AAP. Results of the MTC showed a non-significant trend in favour 
of lithium augmentation for response [lithium odds ratio (OR) 1.29; 95% credible 
interval (95% CrI): 0.11 to 5.32], mean change in Montgomery-Åsberg Depression 
Rating Scale (MADRS) score from baseline (mean difference -1.47; 95% CrI: -9.10 to 
6.41) and all-cause withdrawals (OR 0.74; 95% CrI: 0.10 to 2.66). ConClusions: In 
patients with TRD, there is a lack of direct evidence comparing the clinical effective-
ness of augmenting an SSRI with an AAP compared with augmenting with lithium. 
Augmentation of SSRIs with lithium or AAP is likely to be beneficial in people with 
TRD. The limited evidence indicates no statistically significant difference between 
the two augmentation strategies.
PMH10
relatiOnsHiP Of insigHt witH MedicatiOn adHerence and tHe iMPact 
On OutcOMes in Patients witH scHizOPHrenia and biPOlar disOrder: 
results frOM a 1-year eurOPean OutPatient ObservatiOnal study
Novick D.1, Montgomery W.2, Treuer T.3, Aguado J.4, Kraemer S.5, Haro J.M.6
1Eli Lilly Holdings Limited, Windlesham, UK, 2Eli Lilly Australia, Sydney, Australia, 3Eli Lilly & 
Company, Budapest, Hungary, 4Parc Sanitari Sant Joan de Deu, CIBERSAM, Sant Boi de Llobregat, 
Spain, 5Eli Lilly and Company Ltd, Bad Homburg, Germany, 6Parc Sanitari Sant Joan de Déu, 
CIBERSAM, Universitat de Barcelona, Barcelona, Spain
objeCtives: Many patients with schizophrenia and bipolar disorder have 
impaired insight and low medication adherence. The aim of this post-hoc anal-
ysis is to explore the relationship between insight and medication adherence 
and their impact on the outcomes of patients with schizophrenia or bipolar 
disorder. Methods: We included 903 patients with schizophrenia or bipolar dis-
order who participated in an observational study conducted in Europe on the out-
comes of patients treated with two oral formulations of olanzapine over a 1-year 
period. Evaluations included Clinical Global Impression (CGI), Global Assessment 
of Functioning (GAF), insight (Scale to Assess Unawareness of Mental Disorder, 
SUMD), non-adherence (Medication Adherence Rating Scale, MARS), and therapeutic 
alliance (Working Alliance Inventory, WAI). Correlations between variables were 
assessed by Spearman Correlation Coefficient (SCC). A path analysis was used to 
understand the relationship between insight, adherence, therapeutic alliance and 
outcomes. Results: 67.8% of patients had schizophrenia. GAF score was higher 
in bipolar vs schizophrenia patients (mean (SD) 58.4 (15.6) vs 51.9 (15.7), p< 0.001). 
Medication adherence was also higher in bipolar patients (mean MARS score (SD) 6.5 
(2.8) vs 5.8 (2.7); p< 0.001). Patients with schizophrenia had lower insight (i.e. SUMD 
item 1, unawareness of mental disorder, mean (SD) of 2.5 (1.3) in schizophrenia vs 
1.9 (1.2) in bipolar, p < 0.001). Better insight was associated with higher adherence 
(SCC, ranging from 0.39 to 0.49 for the three SUMD general items, p< 0.0001 in all 
cases) Higher insight was related to a stronger therapeutic alliance (SCC ranging 
from 0.38 to 0.48, p< 0.0001). The path analysis revealed a positive impact of insight 
on adherence and alliance and that stronger alliance was related to lower clinical 
severity (lower CGI score). ConClusions: Insight and adherence were found to 
be closely related. Insight impacts on the therapeutic alliance with mental health 
professionals. These factors are associated to treatment outcomes.
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objeCtives: In schizophrenia, negative symptoms - especially emotional with-
drawal (EW) - represent an important dimension, and are associated to a significant 
burden. Social contacts are likely to reduce negative symptoms and ameliorate 
quality of life (QoL) over time. Our objective was to test whether this hypothesis was 
verified in a large cohort of European patients with schizophrenia. Methods: We 
